- Advertisement -

Related

Resscapital’s Key Appointment in Pursuit of Awareness

- Advertisement -

Stockholm (HedgeNordic) – To capitalise on strong performance and continued asset growth in 2022, Resscapital made a key appointment to its investor sales and relations team. The asset manager of Ress Life Investments – a fund that seeks to generate uncorrelated, equity-like returns with low volatility in the secondary market for life settlements – has appointed Hanna Persson as Head of Sales and Investor Relations.

“Today marks a new chapter for me. I’m very excited about joining the fantastic team at Resscapital AB in Stockholm, who offers truly diversifying, stable returns,” Hanna Persson announces on LinkedIn. “Looking forward to reconnect with everyone from my new home,” she adds. “Welcome Hanna! So much looking forward to working together and taking our award-winning fund, Ress Life Investments, to new heights,” comments Jonas Martenson, the founder of Resscapital. 

Persson joins Resscapital from Stockholm-based asset manager East Capital, where she served as Senior Client Relationship Manager. Prior to joining East Capital in September 2021, Persson worked at now-closed systematic investment manager IPM Informed Portfolio Manager in various roles for close to 11 years. Persson’s most recent role at IPM was as Senior Director, Head of Consultant and Investor Relations. 

Hanna Persson will focus on increasing awareness to the attractive investment characteristics of a life insurance portfolio and bring Ress Life Investments to wider investor audience. Ress Life Investments is an alternative investment fund investing in life settlements, which involves buying life insurance policies for one-time payments from policy owners who no longer need or want their policies.  

The fund returned 8.5 percent in 2022, its second-best annual performance since launching in 2011. Under the stewardship of Head of Portfolio Management Anton Pozine, Ress Life Investments has delivered an annualized return of 7.8 percent in U.S. dollars over the past five years. “The performance in 2022 clearly shows the fundamentally uncorrelated return of a life insurance portfolio,” says Gustaf Hagerud, Managing Director at Resscapital. “The asset class offers both a good risk diversification and a counter-cyclical return.” 

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Systematic Multi-Strategy as a Portfolio Diversifier

By Fredrik Langenskiöld – Union Bancaire Privée: Multi-strategy funds are those that allocate to more than one alternative strategy or portfolio manager (PM) in...

Visio Allocator Delivers Record Month on AI Chip Rally

After a more muted, albeit still challenging, first quarter, multi-strategy fund Visio Allocator regained momentum starting in April and delivered its strongest month on...

Colosseum’s Difficult Stretch Continues as Co-Portfolio Manager Departs

After a volatile journey since launching in mid-2025, Colosseum Global Alpha has suffered two consecutive months of steep losses, leaving the fund down more...

CABA Offers Another Roll Down the Curve

CABA Capital has launched the fourth iteration of its Flex strategy, a three-year closed-ended AAA-yield premium strategy designed to harvest roll-down and pull-to-par effects...

Even Steven for Nordic CTAs in Mediocre May

May was another month characterized by reversals and cross-asset volatility. Strong momentum in U.S. equities contrasted with directionless moves across other markets, creating a...

Rhenman Doubles Down on Smaller Healthcare Innovators with New Fund

Many of healthcare’s most transformative breakthroughs often originate not from established industry giants, but from smaller companies developing new technologies, therapies, and treatment approaches....

Allocator Interviews

In-Depth: Diversification

- Advertisement -

Voices

Request for Proposal

- Advertisement -